Natural History and Biomarker Studies of Rare Neurodegenerative Diseases (U01) Clinical Trials Optional

The purpose of this funding opportunity announcement (FOA) is to support efficient natural history studies and/or biomarker studies that fill unmet needs for rare neurodegenerative diseases for children and adults. Through the support of prospective natural history and/or biomarker studies with high quality and interpretable data elements, FDA expects to address critical knowledge gaps, remove major barriers to progress in the field, exert a significant and broad impact on a specific rare neurodegenerative disease or multiple rare neurodegenerative diseases with similar pathophysiology, and facilitate rare disease product development.
Categories: Consumer Protection, Science and Technology and other Research and Development.